Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2018 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about deals, orders, contracts, projects, customers, sites, or programs. We need to see if management conveys that the individual size of what they land now is bigger than before for the same offering. Looking at the transcript: They discuss value-add initiatives, capital recycling, acquisitions. They mention acquiring two properties: a 348-unit in Tampa and a 232-unit in Columbus. They talk about the value-add program with phases. They mention that renovated units are generating rent premiums. They talk about the capital recycling plan to sell five assets and recycle proceeds into acquisitions. They mention that they are targeting markets and will acquire properties. But do they say that the deals they are landing now are individually larger than before? They don't seem to compare deal sizes over time. They talk about the scale of their portfolio, but not about the size of individual acquisitions increasing. They mention that they have a pipeline and will be opportunistic. But there's no explicit statement that the average size of acquisitions has stepped up versus the past. They might be acquiring more properties, but not necessarily larger ones. The question is about the unit size of the company's own repeatable business escalating. The business is acquiring and managing multifamily properties. The "deals" are acquisitions. They don't say that the acquisitions are getting bigger. They mention two acquisitions: one 348 units, one 232 units. But they don't compare to past acquisitions. They also talk about value-add projects, but those are internal renovations, not new engagements. They talk about the capital recycling program, but that's about selling and buying. No mention of larger deals. Thus, the answer is NO. They don't convey that the size of each new deal is larger than before. They might be doing more deals, but not larger ones. Also, they don't mention that the projects are longer or broader. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.